Triple negative breast cancer (TNBC) is an aggressive type of breast cancer characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). TNBC accounts for approximately 10-20% of all breast cancer cases diagnosed globally. TNBC tumors are more likely to be high grade, tend to grow and spread more quickly than other breast cancer types and have a poorer long-term prognosis. However, treatments for TNBC have been limited compared to other breast cancer subtypes.
The triple negative breast cancer (TNBC) treatment market is estimated to be valued at USD 1000 million in 2024 and is expected to reach USD 1432 million by 2031, growing at a compound annual growth rate (CAGR) of 5.3% from 2024 to 2031.
The global geopolitical landscape has seen much uncertainty and instability over the past few years due to various reasons such as rising nationalism, trade wars, and security issues. This has impacted the growth of the Triple Negative Breast Cancer (TNBC) Treatment Market as well. Growth in this market is dependent on R&D investments, availability of funding for clinical trials, collaborations between market players etc. Geopolitical tensions tend to divert investments and slow down cross-border partnerships in healthcare.
Get More Insights On- Triple Negative Breast Cancer (TNBC) Treatment Market
Get This Report in Japanese Language: トリプルネガティブ乳がん（TNBC）治療市場
Get This Report in Korean Language: 삼중 음성 유방암(TNBC) 치료 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian